Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).

× No keyword cloud information.

47 in total

1. Plastic surgery: treatment of melanoma.

Authors: S Blois; W Epstein; R Dakin; M Gromet
Journal: West J Med Date: 1976-08

Review 2. Topoisomerases, new targets in cancer chemotherapy.

Authors: J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal: Med Oncol Tumor Pharmacother Date: 1990

3. Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives.

Authors: Guillermo Rodriguez-Berna; Maria Jose Díaz Cabañas; Victor Mangas-Sanjuán; Marta Gonzalez-Alvarez; Isabel Gonzalez-Alvarez; Ibane Abasolo; Simó Schwartz; Marival Bermejo; Avelino Corma
Journal: ACS Med Chem Lett Date: 2013-05-28 Impact factor: 4.345

Review 4. Topoisomerases as anticancer targets.

Authors: Justine L Delgado; Chao-Ming Hsieh; Nei-Li Chan; Hiroshi Hiasa
Journal: Biochem J Date: 2018-01-23 Impact factor: 3.857

5. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.

Authors: L J van Warmerdam; J Verweij; J H Schellens; H Rosing; B E Davies; M de Boer-Dennert; R A Maes; J H Beijnen
Journal: Cancer Chemother Pharmacol Date: 1995 Impact factor: 3.333

Review 6. Topoisomerase inhibitors. A review of their therapeutic potential in cancer.

Authors: B K Sinha
Journal: Drugs Date: 1995-01 Impact factor: 9.546

7. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice.

Authors: T Matsuzaki; T Yokokura; M Mutai; T Tsuruo
Journal: Cancer Chemother Pharmacol Date: 1988 Impact factor: 3.333

Review 8. Clinical pharmacokinetics of topotecan.

Authors: V M Herben; W W ten Bokkel Huinink; J H Beijnen
Journal: Clin Pharmacokinet Date: 1996-08 Impact factor: 6.447

9. Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity.

Authors: Rupa R Sawant; Rishikesh M Sawant; Vladimir P Torchilin
Journal: Eur J Pharm Biopharm Date: 2008-04-29 Impact factor: 5.571

10. Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.

Authors: Z M Prijovich; B-M Chen; Y-L Leu; J-W Chern; S R Roffler
Journal: Br J Cancer Date: 2002-05-20 Impact factor: 7.640